

全部

新闻

图片

购物

地图

更多

设置

工具

找到约 243,000 条结果 (用时 0.52 秒)

Google 学术 : Recent progress of PD-1/PD-L1 inhibitors in immunotherapy of gastric cancer

... signaling inhibition for cancer immunotherapy: ... - Alsaab - 被引用次数 : 184

PD-1/PD-L1 blockade in cancer treatment: ... - Hamanishi - 被引用次数 : 109

... postoperative recurrence in hepatocellular carcinoma ... - Shi - 被引用次数 : 240

Development of PD-1 and PD-L1 inhibitors as a form of cancer ...

<https://jitc.biomedcentral.com/articles/10.1186/s40425-018-0316-z> ▼ 翻译此页

作者 : J Gong - 2018 - 被引用次数 : 79 - 相关文章

2018年1月23日 - As the number of PD-1/PD-L1 inhibitors continues to grow, ... form of cancer immunotherapy given that activation of the PD-1/PD-L1 axis ...

Immunotherapy in Advanced Gastric Cancer: An Overview of the ...

<https://www.hindawi.com/journals/cjgh/2018/2732408/> ▼ 翻译此页

作者 : H Magalhães - 2018 - 被引用次数 : 2 - 相关文章

2018年3月19日 - It is known that PD-L1 is highly predictive in lung cancer, but yet controversial in gastric cancer. ... interacts with its receptor PD-1 and this consequently leads to inhibition of the T-cells migration, In conclusion, some progress has been reached in the treatment of advanced gastric cancer in the last years.

Evolution of checkpoint inhibitors for the treatment of metastatic gastric ...

<https://www.ncbi.nlm.nih.gov/pubmed/29730461> - 翻译此页

作者 : J Taieb - 2018 - 被引用次数 : 10 - 相关文章

2018年4月22日 - Recently, immunotherapy with antibodies that inhibit the programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) interaction has ...

Name of Journal: *World Journal of Meta-Analysis*

Manuscript NO: 46535

Manuscript Type: MINIREVIEWS

PD-1/PD-L1 antagonists in gastric cancer: Current studies and perspectives

Jian Li, Xiao-Hong Zhang, Song-Hua Bei, Li Feng

Abstract

Immune checkpoints release suppressive signals for T cells, which enable the tumors to escape from immune destruction, and provide a new concept that uses the capabilities of the immune system as a therapeutic target for tumors. At present, programmed death receptor 1 (PD-1)/programmed death

Match Overview

1	Crossref 156 words Masahiko Amatatsu, Takaaki Arigami, Yoshi kazu Hasegawa, Shigehiro Yanagita et al. "D	4%
2	Crossref 55 words Rutika Mehta, Anand Shah, Khaldoun Almh anna. "Bemrolizumab for the treatment of n	1%
3	Crossref 55 words Yang, Yiping. "Cancer immunotherapy: harm assing the immune system to battle cancer"	1%
4	Internet 49 words crawled on 23-Mar-2018 science.sciencemag.org	1%
5	Internet 40 words crawled on 25-Mar-2019 onlinelibrary.wiley.com	1%
6	Internet 37 words crawled on 18-Mar-2019 journals.plos.org	1%
7	Crossref 20 words Stanciu, Luminita A., Cinzia M. Bellettato, Va sile Laza, Stancu, Anthony J. Coyle, Alberto	<1%
8	Internet 19 words crawled on 28-Nov-2016 pdfs.semanticscholar.org	<1%
9	Crossref 17 words Jie Li, Qi He, Xiu Yu, Khalid Khan, Xuanwen Wang, Minjie Guan "	<1%
10	Internet 17 words crawled on 15-Jul-2017 www.mdpi.com	<1%



国内版

国际版

PD-1/PD-L1 antagonists in gastric cancer: Current studies and perspectives



All

Images

Videos

翻译成中文

关闭取词

778,000 Results

Any time ▾

Antagonists of PD-1 and PD-L1 in Cancer Treatment

www.ncbi.nlm.nih.gov › Journal List › HHS Author Manuscripts

Gynecologic Cancers. One **study** of 115 **cervical cancers** demonstrated PD-L1 expression by 19% of **cervical tumors**, with PD-1 expression in about 50% of TILs (independent of tumor cell PD-L1 expression). 44 PD-L1 expression in **cervical cancer** was not associated with survival outcomes.

Cited by: 124

Author: Evan J. Lipson, Patrick M. Forde, Hans-J...

Publish Year: 2015

Antagonists of PD-1 and PD-L1 in Cancer Treatment ...

<https://www.sciencedirect.com/science/article/pii/S0093775415001116>

The manageable safety profile of PD-1/PD-L1 blocking drugs identifies them as suitable for outpatient administration and the development of combinatorial therapies. ... MPDL3280A also demonstrated activity in a patient with **gastric cancer**. 18 Results from a phase Ib **study** ... which are predicted by preclinical models to be able to increase the ...

Cited by: 124

Author: Evan J. Lipson, Patrick M. Forde, Hans-J...

Publish Year: 2015

Immuno-oncology in GI tumours: Clinical evidence and ...

<https://www.sciencedirect.com/science/article/pii/S1040842818300118>

This paper reviews the clinical evidence end of 2017 and discusses the **clinical** development programs of atezolizumab, avelumab, durvalumab, nivolumab and pembrolizumab in **GI-tract cancers**. Since 2014, these **antagonists** of the PD-1/PD-L1 axis have gained approval for use in numerous other tumors.

Cited by: 1

Author: Alexander Stein, Markus Moehler, Jörg Tr...

Publish Year: 2018

Cancer immunotherapies targeting the PD-1 signaling ...